source
- Biotech Index Retraces Gains as Weak Trial Data and Market Fears WeighBioPharma Dive’s latest data‑visualization piece examines why biotech stocks have slipped recently and highlights the rapid pace of startup acquisitions this year. The XBI index, a barometer for b…
- TRex Bio prices $117M IPO to fund Treg-targeted immune therapiesTRex Bio announced pricing of its initial public offering at $117 million, selling 8,333,334 shares at $14 each, meeting the low end of its earlier guidance. The company will begin trading on Nasd…